Subscribe - Individual

Subscribe - Biotech Premium (Corporate)

Categories

GettyImages14333166911200x6751
July 29th, 2025

Botanix Share Price Falls on Lower than Expected Margins

Whilst Botanix Pharmaceuticals (BOT: $0.165) is making excellent progress in gaining early traction for its new dermatology drug for the treatment of excessive sweating, the low initial gross-to-net margin appears to have surprised investors. This has resulted in the company’s share price falling by 51%.

imugene
July 28th, 2025

Clever Culture Systems Secures Another Major Pharma Customer

Clever Culture Systems (CC5: $0.032) has announced the sale of its APAS Independence instrument to its fourth major customer, Novo Nordisk, the supplier of the weight-loss drug Ozempic. The APAS instrument costs around US $350,000, with the potential for Novo Nordisk to deploy it across its 16 major production facilities (potential sales of US $8.6 million). Novo Nordisk has purchased the instrument to assess its functionality by its centralized team in Denmark. If it performs well, a rollout across all major manufacturing sites can be expected.

medicalsciencelaboratoryportraitbeautiful260nw1922200124
July 26th, 2025

Imugene to Lead with Azer-cel Program into Pivotal Study Following Additional Complete and Partial Responses. Capital Raise for up to $37.5 Million Underway

Imugene (IMU: $0.28) continues to produce very good data from its Phase Ib study with its Azer-cel technology in patients with lymphoma (DLBCL) who have failed multiple lines of previous treatments. DLBCL is one of the most aggressive types of lymphoma.

20210629pxs
July 4th, 2025

Amplia Surges 480% on Pancreatic Cancer Cures

Amplia Therapeutics (ATX: $0.295) is developing a small-molecule drug for the treatment of pancreatic cancer. It is initially trialing the treatment in patients with an advanced form of the disease, metastatic prostate cancer.